biotech

Heart Drug Trasylol May Boost Risk of Death

Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics on October 30, 2007

Foolowing the results of the a study on the efficacy and safety of Trasylol, a drug used to prevent excessive bleeding during heart bypass surgery, the FDA issued a warning that the drug also raises the risk of death in comparison to other drugs. Trasylol, also known as aprotinin, works by blocking enzymes that dissolve blood clots

trasylol.JPG


Bayer said it believes Trasylol remains a safe and effective treatment option, but that the company would work with the FDA and regulators in other countries to re-evaluate the drug's risks and benefits and determine where any label changes are needed.

The FDA said such changes, as well as other, unspecified regulatory actions, may result.


Source: Fox News



Permalink: Heart Drug Trasylol May Boost Risk of Death

Tags: FDA  heart+disease  trasylol  heart+surgery  heart+bypass  biotech  risk+death  drug+trasylol 

Vote for Heart Drug Trasylol May Boost Risk of Death:

  • Currently 9.00/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 9.00 out of 1 vote(s) cast.
 
Share It
RSSrss
Google google
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
TwitterFollow us on Twitter!
Tagcloud
Most Popular   Best of   Biotech Hubs and Facilities   Biotech/Science Blogs   Corporate and Industrial News   Diagnostics, Methodologies and Instrumentation   Did you know   Drugs, Vaccines and Therapeutics   Energy, Environment and Ecology   Food and Agriculture   Gene Therapy   Genomics, Proteomics and Bioinformatics   Information About   Meetings and Other Events   Microbiology   Misc   Nanomedicine   Other Biotechnology News   Patents and Intellectual Property Rights   Quick introduction   Stem Cells